Key result
A FRET-based high-throughput assay was successfully developed and validated for screening inhibitors of viral proteases from SARS-CoV-2 and tick-borne encephalitis virus.
Why the study?
The SARS-CoV-2 pandemic demands affordable and reliable assays for testing antivirals against viral proteases.
Development of a robust, inexpensive, high-throughput FRET-based assay enables efficient screening of inhibitors against RNA virus proteases such as SARS-CoV-2.
May facilitate RNA virus protease inhibitor screening; leaves open translation from this Level 5 animal assay to clinical use.
Spanish flu, polio epidemics, and the ongoing COVID-19 pandemic are the most profound examples of severe widespread diseases caused by RNA viruses. The coronavirus pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demands affordable and reliable assays for testing antivirals. To test inhibitors of viral proteases, we have developed an inexpensive high-throughput assay based on fluorescent energy transfer (FRET). We assayed an array of inhibitors for papain-like protease from SARS-CoV-2 and validated it on protease from the tick-borne encephalitis virus to emphasize its versatility. The reaction progress is monitored as loss of FRET signal of the substrate. This robust and reproducible assay can be used for testing the inhibitors in 96- or 384-well plates.
No takes yet. Share an insight, caveat, or question.
Cihlova et al. (2021) studied RNA viruses (SARS-CoV-2, tick-borne encephalitis virus). FRET-based high-throughput assay was evaluated on Assay performance (loss of FRET signal). A FRET-based high-throughput assay was successfully developed and validated for screening inhibitors of viral proteases from SARS-CoV-2 and tick-borne encephalitis virus.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: